GERMANTOWN, Md., July 1, 2019 /PRNewswire/ -- Neuralstem, Inc.
(Nasdaq:CUR), a biopharmaceutical company focused on developing
novel treatments for nervous system diseases, announced the
publication of a manuscript in Stem Cells Translational
Medicine describing the results of an open label Phase 1
clinical trial evaluating the feasibility and safety of
transplantation of its lead stem cell asset, NSI-566, for the
treatment of motor deficits due to ischemic stroke. The publication
can be found here.
The manuscript, entitled 'Stable Intracerebral Transplantation
of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic
Stroke,' summarizes the results of an open label trial performed at
BaYi Brain Hospital in Beijing,
China, with Principal Investigator Professor Xu Ruxiang. Each of the nine subjects in the
study had sustained chronic motor deficits due to an ischemic
stroke 5-24 months prior to enrollment, and were divided into three
cohorts receiving intracerebral injections of NSI-566 cells
totaling 12, 24, or 72 million cells. Subjects were maintained on
immunosuppressive drugs for 28 days following transplantation and
were monitored for up to 24 months after surgery. The treatment was
well tolerated at all doses and subjects showed stable increases in
Fugl-Meyer Motor Scores from baseline, indicating the procedure is
safe and may have potential to provide benefit to patients with
motor deficits from stroke.
'We are grateful to our collaborators at BaYi Brain Hospital and
to the subjects who participated in the trial,' said Dr.
Ken Carter, Executive Chairman of
Neuralstem. 'Although this is a small feasibility study, we are
encouraged by the safety profile of this procedure, which has led
us to initiate a placebo-controlled trial at this same site in
September of 2018.'
About Ischemic Stroke
Ischemic stroke, the most common type of stroke, occurs as a
result of an obstruction within a blood vessel supplying blood to
the brain. Approximately 15 million people worldwide suffer stroke,
of which approximately 87% are ischemic strokes. Post-stroke motor
deficits include paralysis in arms and legs and can be
permanent.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. The Company has two lead development
candidates:
- NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and
chronic spinal cord injury (cSCI)
- NSI-189, is a small molecule in clinical development for major
depressive disorder and in preclinical development for Angelman
syndrome, irradiation-induced cognitive impairment, diabetic
neuropathy, and stroke
Neuralstem's diversified portfolio of product candidates is
based on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking
Information
This news release contains "forward-looking statements"
made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements relate to future, not past, events and may often be
identified by words such as "expect," "anticipate," "intend,"
"plan," "believe," "seek" or "will." Forward-looking statements by
their nature address matters that are, to different degrees,
uncertain. Specific risks and uncertainties that could cause our
actual results to differ materially from those expressed in our
forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem's
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2017 filed
with the Securities and Exchange Commission (SEC), and in other
reports filed with the SEC. We do not assume any obligation to
update any forward-looking statements.
Contact:
Josh Barer
Hibiscus BioVentures
josh@hibiscusbio.com
View original
content:http://www.prnewswire.com/news-releases/neuralstem-announces-publication-of-results-from-phase-1-clinical-trial-evaluating-human-neural-stem-cells-in-chronic-stroke-patients-300878045.html
SOURCE Neuralstem, Inc.